Literature DB >> 24058931

Reply to K.S. Wilson et al.

Antoni Ribas, Axel Hauschild, Richard Kefford.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24058931     DOI： 10.1200/JCO.2013.50.2120

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Immune checkpoint inhibitors in melanoma.

Authors:  Adam J Cooper; Matteo S Carlino; Richard F Kefford
Journal:  Melanoma Manag       Date:  2015-08-10

2.  CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Authors:  Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

3.  Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Authors:  Zeynep Eroglu; Dae Won Kim; Xiaoyan Wang; Luis H Camacho; Bartosz Chmielowski; Elizabeth Seja; Arturo Villanueva; Kathleen Ruchalski; John A Glaspy; Kevin B Kim; Wen-Jen Hwu; Antoni Ribas
Journal:  Eur J Cancer       Date:  2015-09-10       Impact factor: 9.162

Review 4.  Immune based therapy for melanoma.

Authors:  Robert Ancuceanu; Monica Neagu
Journal:  Indian J Med Res       Date:  2016-02       Impact factor: 2.375
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.